ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
2024年8月1日 - 8:00PM
ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company
focused on the generation and development of therapeutics targeting
toxic misfolded proteins in neurodegenerative diseases, today
announced that Neil Warma, interim Chief Executive Officer of
ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical
Officer of ProMIS Neurosciences, will participate in a fireside
chat at the BTIG Virtual Biotechnology Conference on August 6, 2024
at 12:00 p.m. ET.
A live webcast of the fireside chat will be
available to conference participants.
About ProMIS Neurosciences
Inc.
ProMIS Neurosciences Inc. is a clinical stage
biotechnology company focused on generating and developing antibody
therapeutics selectively targeting toxic misfolded proteins in
neurodegenerative diseases such as Alzheimer’s disease (AD),
amyotrophic lateral sclerosis (ALS) and multiple system atrophy
(MSA). The Company’s proprietary target discovery engine applies a
thermodynamic, computational discovery platform - ProMIS™ and
Collective Coordinates - to predict novel targets known as Disease
Specific Epitopes on the molecular surface of misfolded proteins.
Using this unique approach, the Company is developing novel
antibody therapeutics for AD, ALS and MSA. ProMIS has offices in
Toronto, Ontario and Cambridge, Massachusetts.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to
info@promisneurosciences.com.
For Investor Relations, please
contact: Precision AQAnne Marie Fields, Managing
Directorannemarie.fields@precisionaq.comTel. 212-362-1200
ProMIS Neurosciences (TSX:PMN)
過去 株価チャート
から 8 2024 まで 9 2024
ProMIS Neurosciences (TSX:PMN)
過去 株価チャート
から 9 2023 まで 9 2024